MFN1

Across TCGA pan-cancer cohorts, MFN1 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated MFN1 data layer compared with 22 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher MFN1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MFN1 expression acts as an unfavorable survival marker, although some lineages such as BLCA and STAD show a favorable association.

BRCA, OV, and KIRC are the cancer types where MFN1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.627	0.964	<.001	44	view →
OV	OS	Median	II,III,IV	0.023	0.844	<.001	36	view →
KIRC	OS	Median	All	0.127	0.874	<.001	12	view →
SKCM	DFS	Median	III,IV	0.087	0.647	.013	9	view →
COAD	OS	Median	II,III,IV	0.001	0.860	<.001	7	view →
BLCA	DFS	Median	All	1.000	0.329	.033	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
STAD	OS	Median	IV	1.000	0.299	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

MFN1–BRCA (OS)

Open the BRCA breakdown →